Toward a Functional Cure for Hepatitis B
Gut Liver. 2024 Mar 27. doi: 10.5009/gnl240023. Online ahead of print.ABSTRACTCurrent treatment of chronic hepatitis B virus (HBV) infection, pegylated interferon-α (pegIFN-α) and nucleos(t)ide analogue (NA), can suppress HBV replication, reverse liver inflammation and fibrosis, and decrease risks of cirrhosis and hepatocellular carcinoma, but hepatitis B surface antigen (HBsAg) loss is rare. Functional HBV cure is defined as undetectable HBsAg and unquantifiable serum HBV DNA for at least 24 weeks after a finite course of therapy. This requires suppression of HBV replication and viral protein production as well as resto...
Source: Gut and Liver - March 27, 2024 Category: Gastroenterology Authors: Anna S F Lok Source Type: research
Impact of COVID-19 on pre-existing liver disease
Cir Cir. 2024;92(1):131-136. doi: 10.24875/CIRU.23000409.ABSTRACTPatients with chronic liver disease of any etiology who become infected with SARS-CoV-2 have been found to have a higher risk of mortality compared to those patients who do not have chronic liver disease. A literature review was conducted in the relationship between COVID 19 and preexistence of liver disease. The proportion of COVID-19 patients with abnormal liver function on admission ranged from 40 % to 75 % and the proportion with liver injury was close to 30%. Current studies show an important association between preexisting liver disease and COVID-19. Th...
Source: Cirugia y Cirujanos - March 27, 2024 Category: Surgery Authors: Juan M Abdo-Francis Rosalba Moreno-Alcantar Jos é L Pérez-Hernández Jos é M Remes-Troche Antonio Velarde-Ruiz Velasco Eira Cerda-Reyes F átima Higuera-de la Tijera Graciela Castro-Narro Source Type: research
Toward a Functional Cure for Hepatitis B
Gut Liver. 2024 Mar 27. doi: 10.5009/gnl240023. Online ahead of print.ABSTRACTCurrent treatment of chronic hepatitis B virus (HBV) infection, pegylated interferon-α (pegIFN-α) and nucleos(t)ide analogue (NA), can suppress HBV replication, reverse liver inflammation and fibrosis, and decrease risks of cirrhosis and hepatocellular carcinoma, but hepatitis B surface antigen (HBsAg) loss is rare. Functional HBV cure is defined as undetectable HBsAg and unquantifiable serum HBV DNA for at least 24 weeks after a finite course of therapy. This requires suppression of HBV replication and viral protein production as well as resto...
Source: Gut and Liver - March 27, 2024 Category: Gastroenterology Authors: Anna S F Lok Source Type: research
Impact of COVID-19 on pre-existing liver disease
Cir Cir. 2024;92(1):131-136. doi: 10.24875/CIRU.23000409.ABSTRACTPatients with chronic liver disease of any etiology who become infected with SARS-CoV-2 have been found to have a higher risk of mortality compared to those patients who do not have chronic liver disease. A literature review was conducted in the relationship between COVID 19 and preexistence of liver disease. The proportion of COVID-19 patients with abnormal liver function on admission ranged from 40 % to 75 % and the proportion with liver injury was close to 30%. Current studies show an important association between preexisting liver disease and COVID-19. Th...
Source: Cirugia y Cirujanos - March 27, 2024 Category: Surgery Authors: Juan M Abdo-Francis Rosalba Moreno-Alcantar Jos é L Pérez-Hernández Jos é M Remes-Troche Antonio Velarde-Ruiz Velasco Eira Cerda-Reyes F átima Higuera-de la Tijera Graciela Castro-Narro Source Type: research
Toward a Functional Cure for Hepatitis B
Gut Liver. 2024 Mar 27. doi: 10.5009/gnl240023. Online ahead of print.ABSTRACTCurrent treatment of chronic hepatitis B virus (HBV) infection, pegylated interferon-α (pegIFN-α) and nucleos(t)ide analogue (NA), can suppress HBV replication, reverse liver inflammation and fibrosis, and decrease risks of cirrhosis and hepatocellular carcinoma, but hepatitis B surface antigen (HBsAg) loss is rare. Functional HBV cure is defined as undetectable HBsAg and unquantifiable serum HBV DNA for at least 24 weeks after a finite course of therapy. This requires suppression of HBV replication and viral protein production as well as resto...
Source: Gut and Liver - March 27, 2024 Category: Gastroenterology Authors: Anna S F Lok Source Type: research
